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Brain tissue is particularly susceptible to oxidative stress (OS). Increased production of reactive oxygen species (ROS), reduced
antioxidant systems, and decreased efficiency in repairing mechanisms have been linked to Alzheimer’s disease (AD). Postmortem
studies in AD patients’ brains have shown oxidative damage markers (i.e., lipid peroxidation, protein oxidative damage, and
glycoxidation). Fermented papaya (FPP, a product of Carica papaya Linn fermentation with yeast) is a nutraceutical supplement
with favorable effects on immunological, hematological, inflammatory, and OS parameters in chronic/degenerative diseases. We
studied 40 patients (age 78.2 ± 1.1 years), 28 AD patients, and 12 controls. Urinary 8-OHdG was measured to assess OS. Twenty AD
patients were supplemented with FPP (Immunage, 4.5 grams/day) for 6 months, while controls did not receive any treatment. At
baseline, 8-OHdGwas significantly higher in patients with AD versus controls (13.7 ± 1.61 ng/mL versus 1.6 ± 0.12 ng/mL,𝑃 < 0.01).
In AD patients FPP significantly decreased 8-OHdG (14.1 ± 1.7 ng/mL to 8.45 ± 1.1 ng/mL, 𝑃 < 0.01), with no significant changes
in controls. AD is associated with increased OS, and FPP may be helpful to counteract excessive ROS in AD patients.
1. Introduction
Alzheimer’s disease (AD) is the most common neurodegen-
erative disorder, and its incidence increases with age [1].
AD is characterized by the presence of several pathologi-
cal hallmarks including neuronal loss, formation of senile
plaques composed by extracellular deposits of amyloid beta
(A𝛽) caused by an abnormal processing of amyloid-beta
precursor protein (APP), intracellular neurofibrillary tangles
(NFT) composed of aggregated hyperphosphorylated tau
proteins in brain, proliferation of astrocytes, and activation of
microglial.These features are accompanied by mitochondrial
dysfunction and alterations in neuronal synapses [1]. The
molecular and pathophysiological mechanisms that underlie
AD still have many dark sides. Even though AD is multi-
factorial, its etiology and the exact mechanism that triggers
the pathological alterations are still not clear. Although most
studies have suggested that the A𝛽 peptide (amyloid cascade
hypothesis) may initiate and/or contribute to the pathogene-
sis of AD, the mechanisms through which it causes neuronal
loss, and tau abnormalities still remain poorly understood.
Reactive oxygen species (ROS) and reactive nitrogen species
(RNS), including superoxide anion radical, hydrogen perox-
ide, hydroxyl radical, singlet oxygen, alkoxyl radicals, peroxyl
radicals, and peroxynitrites, contribute to the pathogenesis
of numerous human degenerative diseases [2] and have been
implicated in the pathogenesis of neurodegenerative disor-
ders including AD and Parkinson’s disease, among others [3].
The production of reactive oxygen species (ROS) seems to
be involved in triggering and maintaining the degeneration
cycle of AD, causing the damage of mitochondrial DNA and
of the electron transport chain, which leads to an increased
production of ROS [4]. Brain tissue is particularly susceptible
to oxidative damage. The metabolism of brain tissue requires
high energy levels and it consumes approximately 20% of the
total body oxygen despite the fact that it comprises less than
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2% of total body weight. It is very rich in easily oxidizable
polyunsaturated fatty acids and transition metal, such as
iron and ascorbate, which are key players in oxidation and
facilitate the formation of oxygen free radicals. The brain is
also characterized by a low content of antioxidant systems [5].
The generation of ROS, which are toxic, is a part of
normal metabolism in a biological system. Free radicals are
extremely reactive species, which once formed can start a
series of reactions that are harmful to the cell. It is important
to emphasize that even under normal conditions there is a
physiological cellular production of free radicals, which is
normally counterbalanced by endogenous enzymatic cellular
antioxidants systems. The balance between the production
of reactive oxygen species and antioxidants is essential in a
biological system to prevent adverse effects of oxidative stress.
The damage caused by free radicals is caused by an imbalance
between their production and their neutralization by cellular
antioxidant systems in the human body [6, 7]. Both systems
(production and neutralization) seem to be altered inAD and
these changes have been suggested to play a major role in
the process of age-related neurodegeneration and cognitive
decline [8]. The free radicals thus generated are known
to attack macromolecules such as deoxyribonucleic acid,
proteins, lipids, and carbohydrates. This leads to either onset
or acceleration of degenerative disorders. The main damage
occurs for integration with cellular macromolecules essential
to survival, such as DNA, proteins, and polyunsaturated fatty
acids (whichmake up the cellmembrane) [9].Thus, ROShave
been shown to trigger a variety of damage to cellular DNA
and RNA, causing peroxidation of membranes and neuronal
damage. In addition, the alterations of oxidative metabolism
may render the brain more susceptible to further damage
from A𝛽, which in turn has a prooxidant action [10]. Accu-
mulating evidence suggests that brain tissues in AD patients
are exposed to oxidative stress during the development of
the disease [11]. Oxidative stress and the following cellular
damage caused by protein oxidation, lipid oxidation, DNA
oxidation, and glycoxidation are closely associated with the
development of cognitive decline in AD [9, 12].
Because free radicals and oxidative DNA damage may
have a central role in age-related diseases such as AD, a pro-
tection from oxidative stress, and subsequent DNA damage
may represent a basic approach for elongation of healthy
age and treatment of such age-related diseases. In vitro
antioxidant such as N-acetylcysteine or genetic disruption
of the DNA damage response pathway by checkpoint kinase
deletion can rescue many deficits and eventually elongates
significantly lifespan [13].These observations further indicate
the important role of mitochondria, ROS, and DNA damage
in aging and neurodegenerative diseases. In the past, ran-
domized controlled intervention studies in AD, with antioxi-
dants, such as selegiline or vitamin E, have produced modest
but significant results [14]. Fermented papaya preparation
(FPP), produced by fermentation of Carica papaya Linn by
using yeast, is a food supplement that possesses beneficial and
potent antioxidant properties thatmay be helpful against age-
related and disease-related increase in oxidative stress [15].
FPP exhibits anti-inflammatory, antioxidant, and immunos-
timulatory action and induction of antioxidant enzymes [16].
In neurological conditions, oral administration of FPP
in mice attenuated the reduction of short- and long-term
memory induced by scopolamine [17]. Because of the above-
described role of free radicals in the pathophysiology of
chronic neurodegenerative diseases, it has been suggested a
possible role for the antioxidant action of FPP in counteract-
ing the oxidative stress associated with these conditions [15].
Therefore, we conducted the present study aiming to explore
the effects of oral FPP on oxidative stress in AD patients.
2. Methods
We have measured oxidative stress in patients with initial
or mild AD compared to age-matched control patients
without AD. We have also tested the ability of FPP to
reduce the excessive production of free radicals in patients
with AD [12]. Oxidative stress was assessed by means of an
enzyme immunoassay for the measurement of 8-hydroxy-
2󸀠-deoxyguanosine (8-OHdG) in the urine. Detection of 8-
OHdG, a nucleic acid modification predominantly derived
from hydroxide attack of guanidine, allows for assessment
of more immediate oxidative damage [18]. We studied 40
patients (23 women and 17 men, mean age 78.2 ± 1.1 years)
evaluated at the Alzheimer Evaluation Units of the University
Hospital of Palermo. Twenty-eight patients were recruited
after being diagnosed with early mild AD according to the
criteria of the DSM-IV and NINCDS-ADRDA, while the
other 12 were control patients of the same age.
The patients were not being treated with any other
neurotrophic drug during the whole duration of the study.
The28ADpatientswere divided into two groups; participants
in group 1 (𝑛 = 20 patients) were treated for 6 months with
a supplement of FPP (known commercially as Immunage,
prepared by fermenting the Carica papaya Linn at the Osato
Research Institute, Gifu, Japan) at a dose of 4.5 grams per day
p.o. in a single dose. Patients of group 2 (8 AD patients) did
not receive any treatment.
3. Results and Discussion
The clinical characteristics of the study participants are
shown in Table 1. At baseline, 8-OHdG was significantly
higher in patients with AD versus controls (13.7±1.61 ng/mL
versus 0.12 ± 1.6 ng/mL, 𝑃 < 0.01, Figure 1). In group
1, supplementation with FPP significantly reduced 8-OHdG
levels (from 14.1 ± 1.7 ng/mL to 8.45 ± 1.1 ng/mL, 𝑃 <
0.01, Figure 2), while 8-OHdG did not change significantly
in group 2 (not supplemented), showing a nonsignificant
trend towards an increase (from 12.5 ± 1.9 ng/mL to 19.6 ±
4.1 ng/mL, 𝑃 = NS). In the 20 patients treated with FPP,
oxidative stress as measured by 8-OHdG was reduced in all
but one patient (Figure 3). There were no significant changes
in clinical MMSE evaluation and/or on any other laboratory
parameters examined.
Numerous alterations of oxidative metabolism such as
increased production of ROS metabolites and/or a reduction
in the efficiency of antioxidant systems and repair capability
of damaged molecules are present in AD and have been
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Table 1: Clinical characteristics of study patients.
AD (group 1) baseline before FPP
supplementation AD (group 2) not supplemented Controls without AD
Age (years) 78.1 ± 1.1 78.3 ± 1.0 77.9 ± 1.2 NS
8-OHdG (ng/mL) 14.1 ± 1.7 12.5 ± 1.9 1.6 ± 0.12 <0.001
SBP (mmHg) 132.9 ± 1.9 130.7 ± 2.1 131.0 ± 2.3 NS
DBP (mmHg) 78.6 ± 1.1 77.7 ± 1.2 77.9 ± 1.2 NS
CHOL (mg/dL) 207.9 ± 39 205.8 ± 38 195.7 ± 41 NS
TG (mg/dL) 127.5 ± 47 118 ± 57 112 ± 49 NS
HDL (mg/dL) 43.8 ± 12 47.9 ± 14 47.6 ± 13 NS
LDL (mg/dL) 136.8 ± 35 128.9 ± 40 127.7 ± 41 NS
BMI 24.9 ± 5.5 24.8 ± 6.4 24.1 ± 6.1 NS























Figure 1: 8-Hydroxy-2󸀠-deoxyguanosine (8-OHdG) level in
























Figure 2: 8-Hydroxy-2󸀠-deoxyguanosine (8-OHdG) level in
patients with Alzheimer’s disease (group 1) before and after
fermented papaya powder (FPP) supplementation.
connected to its onset. Mitochondrial oxidative damage has
been found to be excessive in the brains of aged people,
especially AD patients and AD-like transgenic animal mod-
els. The damage caused by oxidative stress is one of the
earliest pathophysiological events in the development of AD;














Figure 3: 8-Hydroxy-2󸀠-deoxyguanosine (8-OHdG) level in each of
the 20 patients with Alzheimer’s disease (group 1) before and after
fermented papaya powder (FPP) supplementation.
and neurofibrillary tangles. Markers of DNA damage, par-
ticularly oxidative DNA damage, have been largely found in
brain regions, peripheral tissues, and biological fluids of AD
patients. Moreover, there is evidence that oxidative damage
is one of the earliest detectable events within the progression
from a normal brain to dementia [9, 19]. Almost one decade
ago, a decrease in the DNA base excision repair activity was
observed in postmortem brain regions of AD individuals,
leading to the hypothesis that the brain in AD might be
subjected to the double insult of increased DNA damage, as
well as deficiencies of DNA repair pathways [20]. Autopsy
studies on brain tissue from AD patients’ brain tissue from
AD patients have confirmed the presence of numerous signs
of oxidative stress, such as A𝛽-induced oxidative DNA dam-
age andmitochondrial dysfunction, together with an increase
in lipid peroxidation, proteins, and glycides oxidation [21],
and a reduction of the antioxidant enzyme systems [22]. In
vitro studies have shown that the neurotoxic properties of
A𝛽 may be mediated by oxygen radicals. Amyloid deposits
are associated with an overexpression of markers of oxidative
stress, increased structural abnormalities of mitochondria,
and mitochondrial DNA damage [23].
4 Mediators of Inflammation
Age is the greatest risk factor for AD. Aging and chronic
diseases are themselves associated with an increase in oxida-
tive stress.The concentrations of oxidative-damagedproteins,
lipids, and DNA have been reported to increase with age.
This increase of oxidative stress during the aging process
may contribute in part towards neurodegeneration in AD.
The temporal association of the age related increased levels
of ROS with the formation of the senile plaque provides
further evidence that aging-induced alterations in brain
oxidative status may be a major factor in triggering enhanced
production and deposition of A𝛽 in AD [19].
We have previously shown that chronic diseases, such
as diabetes mellitus type 2 or cardiovascular conditions,
accelerate the age-dependent increase in oxidative stress
[24]. A further derangement in oxidative stress balance
may be caused by chronic inflammation of aging. Aging is
characterized by a chronic, low-grade inflammation, and this
phenomenon has been termed as inflammaging [25]. Aging
and chronic disease create a cascade of events that can be
best characterized as an asymptomatic inflammatory process.
This cascade of events is mediated by cytokine interleukins 1
and 6 (IL-1alpha, and IL-6), nitric oxide (NO), and oxidative
stress [26]. Inflammation has been suggested to be another
responsible factor in AD and is presumed to be mediated
through the cross talk among the amyloid, astrocytes, and
microglia [27].These reactions lead to altered neuronal func-
tion and the inflammatory injury. Thus, in patients with AD
wehave recently shown an increase of oxidative stress [12] and
an alteration of the immunoinflammatory responses, with
an increased cytokine production, that may have a potential
causal role in contributing to an augmented oxidative stress
[28]. Several studies have shown that A𝛽 may produce an
increase in oxidative stress via several mechanisms, either
increase in ROS production, decrease in the enzyme activ-
ities involved in the antioxidant defense system, or altering
mitochondria function. Nerve cell insults caused by A𝛽 brain
deposition may itself induce oxidative changes [29], and
metals concentrated in amyloid deposits, such as copper,
may as well contribute to the oxidative insults observed in
AD-affected brains. Several studies suggest that A𝛽 increases
oxidative stress by increasing lipid peroxidation measured
by increased levels of thiobarbituric acid-reactive substances
in brain [29]. In addition to lipids, it has been suggested
that ROS-mediated reactions with proteins lead to oxidative
damage of proteins and DNA in the brain tissue [30]. The
accumulation of oxidative stress metabolites present in old
age may itself cause an increase susceptibility of the brain to
damage from neurotoxic peptides such as soluble or fibrillar
A𝛽. As the accumulation of A𝛽 can in turn cause a further
production of ROS, it is still unclear whether the excess
of oxidative stress is a primary or secondary event in AD.
Although there are accumulating evidences suggesting that
oxidative stress may be an early event in the onset of AD, this
aspect seems to be of relative importance, as the production
of ROS, even if secondary, is in turn detrimental to the brain
tissue and can further contribute to neuronal damage [31].
This suggests that any effort to the removal and/or prevention
of ROS formation may be useful in people with AD [29]. For
example, when A𝛽 has started to aggregate and deposit in
the brain, this protein elicits a neuroinflammatory response
via the activation ofmicroglia and astrocytes [32, 33]. Follow-
ing the initial neuroinflammatory response, the neurotoxic
by-products of inflammation cause additional oxidative dam-
age to cells. Similarly, the hyperphosphorylated tau fibrils cre-
ate cytoskeletal stresses and promote neuronal dysfunction
[34].
Oxidative stress-induced cell damage and inflammation
are implicated in a variety of age-related diseases other
than neurodegenerative disorders (such as cancers, dia-
betes, arthritis, and cardiovascular dysfunctions) and aging.
All these conditions could potentially benefit from func-
tional nutraceutical/food antioxidant supplements. Antiox-
idant defenses may potentially protect the body from the
detrimental effects of free radicals. Physiological antioxidants
in food such as fruits and vegetables provide a reasonable
amount of antioxidants. Although existing knowledge is not
definitive, there is rational basis to suggest that antioxidant
supplementation and food plant extracts may help protect
against a number of neurological diseases in which oxidative
stress is implicated andmay have a role in the prevention and
treatment of age-related disease.
It has been suggested that substances with antioxidant
properties or that enhance the endogenous defense system
against free radicalsmay have a role in preventing the onset or
in slowing the progression of AD [35]. Dietary antioxidants
contribute to increased levels of cellular antioxidant ability,
thus decreasing the toxicity of ROS.
FPP has been shown to reduce apoptosis related to
oxidative stress and activation of inflammatory cytokines [36,
37] and to contrast theDNAdamage related to the production
of free radicals induced by several prooxidant substances,
including iron ions, copper, benzopyrene, methylguanidine,
and aluminum, among others [15, 38–40].
In particular, it has been shown that FPP exerts sev-
eral protective actions; it inhibits lipid peroxidation [41]; it
enhances enzyme antioxidant activities such as glutathione
S-transferase in hepatocytes [36] and showed remarkable
hepatoprotective activity [42]. In vitro in a cellular model
of AD, FPP has neuroprotective activity against 𝛽-amyloid-
mediated copper neurotoxicity in 𝛽-amyloid precursor pro-
tein in a cell culture system [36]. FPP has shown protective
properties against iron-mediated oxidative damage to DNA
and proteins [43]. In the brain tissue, FPP has been shown
to have a neuroprotective effect from oxidative damage, from
lipid peroxide level, and superoxide dismutase activity in
iron-induced epileptic foci of rats [41]. At the neuronal level,
FPP has been shown to have a neuroprotective action, to
improve the oxidative status in human neuronal cells and to
protect from insults by oxidative stress linked, for example,
to the cytotoxicity by aluminum in neuronal cells [44].
Neuroprotective potential evaluated in an AD cell model
showed that the toxicity of the A𝛽 can be significantly
modulated and/or reduced by FPP. In vitro FPP has been
shown to protect cells by the oxidative damage related to
the deposition of A𝛽. Treatment with FPP increased the
survival of neuronal cells, preventing apoptosis, and was
able to decrease the production of hydroxyl radicals and
superoxide anion in the cells, aswell as decreasing nitric oxide
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accumulation and intracellular calcium ion [36]. Noda et al.,
using an ESR technique, confirmed the potent antioxidant
inhibitory effect of the FPP, by demonstrating its hydroxyl
radical scavenging activity, its superoxide anion radical scav-
enging activity (SOD-like activity), and its inhibitory effect on
hydroxyl radical generation from methylguanidine [40]. At
the clinical level, studies in chronic and degenerative disease
conditions (i.e., thalassemia, cirrhosis, and diabetes) showed
that FPP favorablymodulates immunological, hematological,
inflammatory, vascular, and oxidative stress damage parame-
ters [15].
Our results suggest that FPP has antioxidant actions in
AD patients and that it may be prophylactic food against
the age-related and neurological diseases associated with
free radical overproduction. Our data confirm that AD is
associated with an increased oxidative stress and that the
FPP can be useful in helping to counteract the excessive
production of free radicals present in patients with AD [12].
The previous in vitro studies are promising and proven
preventive action on the damage from A𝛽 suggesting that
it would also be useful to evaluate the action of FPP in the
more advanced stages of the disease and in combination with
neurotrophic drugs. It would also be interesting to identify
the component of FPP neurotrophic action.
In conclusion, dietary factors can modulate physiological
functions (including brain function) thereby increasing the
economic productivity of a population as a function of health.
A greater understanding of the molecular mechanisms of
neuroprotection, oxidative stress, and immune function will
facilitate definition of the prophylactic potentials of diet,
nutritional/food supplements, medicinal plants, and herbal
extracts. Although the role of oxidative stress in aging
and neurodegenerative and other related diseases is largely
accepted, the value of antioxidant strategies is still debatable.
This becomes more important when, apart from foods or
reasonable lifestyle changes, antioxidant supplements are
considered. Well-defined long-term trials are still needed to
assess the efficacy of antioxidant strategies or of antioxidant-
rich nutritional intervention. Future studies of longer dura-
tion and with a larger number of subjects would be useful to
assess the potential clinical actions of FPP and the possible
relevance to the reduction of oxidative stress on the natural
history of the disease.
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